Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's ...

Adults should discuss with their doctors about whether this vaccine is necessary. It is recommended that adults 50 and older ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Merck & Co beat Wall Street estimates for quarterly earnings on Thursday on strong sales of its blockbuster cancer treatment ...

(Reuters) - Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine -- Ten shingles cases would have been expected absent ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...